332: Pfizer's new R&D head, a VC deep-dive, and a new FDA commissioner?

331: AbbVie’s stumble, Amgen’s tumble and more election fallout

330: How a Trump presidency could affect the FDA, the biotech industry, and its stocks

329: Lilly's earnings surprise, investors mull the election, & a spooky ghost story

328: Pfizer's activist troubles, gene therapy questions, RFK Jr.'s MAHA ambitions

327: Biotech's next gold rush, GLP-1 shortages, and STAT Summit highlights

326: Crypto for CRISPR, a new RNAi startup, & a Nobel for AI

325: Biden's health care AI czar, a new obesity company, and its dealmaking CEO

From Tradeoffs: Race to the Bottom

324: Genentech's cancer pivot, Pfizer's sickle cell withdrawal, and a new schizophrenia drug

323: Cannabinoids for weight loss, a cancelled ad comm, and the Fed lowers interest rates

322: A new threat to Merck's blockbuster cancer treatment, Moderna's cutbacks, and obesity drugs for kids

321: Summit's upcoming cancer results, Recursion's mixed data, and the next big obesity target

320: Jim Wilson's next venture, a surprise startup shutdown, & Lilly's Zepbound strategy

From "Say More": What Happens When AI Decides Your Medical Coverage

319: BioMarin's executive shakeup, a GLP-1 lowers diabetes risk, and a deep look at Recursion's AI bona fides

318: Drug pricing drops & psychedelics under fire

317: VC struggles, drug pricing negotiations, & Novo's abrupt Wegovy decision

316: The long journey to make malaria vaccines, and Sarepta's ties with patient advocates

315: UnitedHealth's doctor empire, an FDA departure, and Viking's obesity moves